BI 1820237
Alternative Names: BI-1820237Latest Information Update: 28 Jul 2024
At a glance
- Originator Boehringer Ingelheim
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Obesity(Combination therapy, In volunteers) in Germany (SC, Injection)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Obesity(Monotherapy, In volunteers) in Germany (SC, Injection)
- 15 Apr 2024 Boehringer Ingelheim initiates a phase I trial for Obesity in Germany (SC) (NCT06352424) (EUCT2023-506233-30-01)